ReviewFrontiers in pharmacology2020
A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs.
Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- COVID-19 in comorbid chronic diseased patients, pregnant and lactating women: pathophysiology, available drug treatment, and the most suitable protocol regimen in each group.Inflammopharmacology · 2025Pooled it
- Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2021Pooled it
- Trial
- Wrangling Real-World Data: Optimizing Clinical Research Through Factor Selection with LASSO Regression.International journal of environmental research and public health · 2025Article
- An Efficient Electrochemical Sensor Based on NiCoBiosensors · 2023Article
- Efficacy and Safety of Sitagliptin in the Treatment of COVID-19.Journal of pharmacy practice · 2023Review
- Polymeric Materials as Indispensable Tools to Fight RNA Viruses: SARS-CoV-2 and Influenza A.Bioengineering (Basel, Switzerland) · 2022Review
- Article
- COVID-19 and the cardiovascular system-current knowledge and future perspectives.World journal of clinical cases · 2022Review
- The Mechanisms of Zinc Action as a Potent Anti-Viral Agent: The Clinical Therapeutic Implication in COVID-19.Antioxidants (Basel, Switzerland) · 2022Review
- Three-Dimensional Visualization of Viral Structure, Entry, and Replication Underlying the Spread of SARS-CoV-2.Chemical reviews · 2022Review
- COVID-19 Vaccine Hesitancy and Determinants of Acceptance among Healthcare Workers, Academics and Tertiary Students in Nigeria.Vaccines · 2022Article
- An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19).International immunopharmacology · 2022Review
- Biology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the humoral immunoresponse: a systematic review of evidence to support global policy-level actions and research.Global health journal (Amsterdam, Netherlands) · 2022Review
- Covid-19: pharmacotherapeutic insights on various curative approaches in terms of vulnerability, comorbidities, and vaccination.Inflammopharmacology · 2022Review
- Article
- Therapeutics for COVID-19 and post COVID-19 complications: An update.Current research in pharmacology and drug discovery · 2022Review
- Induced pluripotent stem cells: Generation methods and a new perspective in COVID-19 research.Frontiers in cell and developmental biology · 2022Review
- Repurposing of Chemotherapeutics to Combat COVID-19.Current topics in medicinal chemistry · 2022Article
- Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For the initial phase of pandemic of coronavirus disease 2019 (COVID-19), repurposing drugs that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.